Performance of tumor markers for assessing bladder cancer spread
Abstract
The article provides novel information about the concentrations of CYFRA 21-1, TPA, TPS, UBC, NMP-22, BTA and CEA tumor markers in body fluids of stage I-IV bladder cancer patients. The study comprised 945 bladder cancer patients and 120 clinically healthy individuals. Bladder cancer was morphologically verified in all patients. Data were analyzed using nonparametric statistical methods. Выявлены информативные показатели для дооперационной оценки степени инвазии опухоли мочевого пузыря (CYFRA 21-1, UBC, NMP-22, BTA), количества опухолевых очагов (TPA, TPS, UBC), степени злокачественности (NMP-22). Markers with reasonable performance for preoperative assessment of bladder cancer invasion (CYFRA 21-1, UBC, NMP-22, BTA), number of tumor foci (TPA, TPS, UBC) and tumor grade (NMP-22) were identified. Sensitivity and specificity of all markers were defined.
About the Author
L. A. Derzhavets
ГУ «РНПЦ онкологии и медицинской радиологии им. Н.Н. Александрова», г. Минск, Беларусь
Russian Federation
Russian Federation
References
1. Молекулярные маркеры в диагностике мышечно-неинвазивного рака мочевого пузыря / П.В. Глыбочко [и др.] // Клин. лаб. диагностика. - 2011. - № 5. - С. 16-20.
2. Онкомаркеры в диагностике стадии инвазии рака мочевого пузыря / А.Н. Понукалин [и др.] // Мед. вестник Башкортостана. - 2013. - Т. 8, № 2. - С.213-217.
3. Тарасов, Н.И. Применение мочевого маркера UBC (urinary bladder cancer antigen) в диагностике рецидивов рака мочевого пузыря после ТУР / Н.И. Тарасов, Д.В. Гуменецкий // Урал. мед. журн. - 2009. - № 4. - С. 122-126.
4. Уринарный и сывороточные цитокератины в ранней диагностике рака мочевого пузыря / Е.В. Рязанцев [и др.] // Вестник РНЦРР МЗ РФ. - 2011. - № 11. - С. 283-292.
5. Bladder cancer screening with urine-based tumour markers - occupational medical experience / M. Nasterlack [et al.] // Aktuelle urologie. - 2011. - Vol. 42, № 2. - P. 128-134.
6. Clinical usefulness of CEA, CA19-9, andCYFRA21-1 as tumormarkers for urothelial bladder carcinoma / S. Washino [et al.] // Urol. Int. - 2011. - Vol. 87, № 4. - P. 420-428.
7. Comparative analysis of sensitivity to blood in the urine for urine-based point-of-care assays (UBC rapid, NMP22 Bladder Chek andBTA-stat) in primary diagnosis of bladder carcinoma. Interference of blood on the results of urine-based POC tests/ G. Ludecke [et al.] // Anticancer Res. - 2012. - Vol. 32, № 5. - P. 2015-2018.
8. Diagnostic values of urine CYFRA21-1, NMP22, UBC, and FDP for the detection of bladder cancer / S. Jeong [et al.] // Clin. Chim.- 2012. - Vol. 414. - P. 93-100.
9. Influencing factors on theNMP-22 urine assay: an experimental model / M. Miyake [et al.] // BMC Urol. - 2012. -Vol. 12. - P. 23.
10. NMP-22, urinary cytology and cystoscopy: a 1 year comparison study / A. Schlake [et al.] // Can. J. Urol. - 2012. - Vol. 19, № 4. - P. 6345-6350.
11. Prognostic significance of preoperative serum CYFRA21-1 in patients with upper urinary tract urothelial carcinoma / T. Suyama [et al.] // Int. J. Urol. - 2011. - Vol. 18, № 1. - P. 43-47.
12. Prognostic value of tissue-polypeptide specific antigen (TPS) in bladdercancer/ V. Menendez Lopez [et al.] // Anticancer Res. - 2002. - Vol. 22, № 6. - P. 3713-3716.
13. Role of cytokeratins, nuclear matrix proteins, Lewis antigen and epidermal growth factor receptor in human bladder tumors / A. Di Carlo [et al.] // Int. J. Oncol. - 2003. - Vol. 23, № 3. - P. 757-762.
14. Use of the NMP22 Bladder Chek test in the diagnosis and follow-up of urothelial cancer: a cross-sectional study / E.C. Hwang [et al.] // Urology. - 2011. - Vol. 77, № 1. - P. 154159.
Review
For citations:
Derzhavets L.A. Performance of tumor markers for assessing bladder cancer spread. Medical and Biological Problems of Life Activity. 2017;(1):128-134. (In Russ.)
Views: 86
Email this article 